Pfizer articles
-
Pfizer lifts profit view on cost cuts, smaller drop in demand for COVID products
Shares of the U.S. drugmaker have lost 11% of their value this year on worries over its growth after the pandemic as billions of dollars in COVID vaccine and treatment sales evaporated. Pfizer reiterated its annual revenue forecast of $8 billion from the sale of COVID-19 shot Comirnaty and anti-viral treatment Paxlovid. Revenue from Comirnaty, for which it partners with Germany's BioNTech, continues to perform consistently with its expectations, Pfizer said.
-
Look ahead: Fed rate decision; Japan consumer confidence; eBay; Pfizer; Qualcomm
US interest rates are expected to stay on hold. Japan releases its latest consumer confidence print. After Amazon's results, investors brace...
-
Look ahead: Fed rate decision; Japan consumer confidence; eBay; Pfizer; Qualcomm
US interest rates are expected to stay on hold. Japan releases its latest consumer confidence print. After Amazon's results, investors brace...